1.28
-0.05 (-3.76%)
Penutupan Terdahulu | 1.33 |
Buka | 1.33 |
Jumlah Dagangan | 9,285,595 |
Purata Dagangan (3B) | 10,468,019 |
Modal Pasaran | 815,255,040 |
Harga / Jualan (P/S) | 7.28 |
Harga / Buku (P/B) | 3.04 |
Julat 52 Minggu | |
Tarikh Pendapatan | 7 Aug 2025 |
Margin Keuntungan | -119.54% |
Margin Operasi (TTM) | -42.18% |
EPS Cair (TTM) | -0.210 |
Pertumbuhan Hasil Suku Tahunan (YOY) | 12,927.30% |
Jumlah Hutang/Ekuiti (D/E MRQ) | 45.40% |
Nisbah Semasa (MRQ) | 7.86 |
Aliran Tunai Operasi (OCF TTM) | -204.34 M |
Aliran Tunai Bebas Leveraj (LFCF TTM) | -142.38 M |
Pulangan Atas Aset (ROA TTM) | -16.07% |
Pulangan Atas Ekuiti (ROE TTM) | -45.35% |
Arah Aliran Pasaran
Jangka Pendek | Jangka Sederhana | ||
Industri | Biotechnology (US) | Bercampur | Menurun |
Biotechnology (Global) | Bercampur | Menurun | |
Stok | Geron Corporation | Menurun | Menurun |
AISkor Stockmoo
Konsensus Penganalisis | -4.5 |
Aktiviti Orang Dalam | NA |
Volatiliti Harga | 0.5 |
Purata Bergerak Teknikal | -2.5 |
Osilator Teknikal | -2.5 |
Purata | -2.25 |
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology. |
|
Sektor | Healthcare |
Industri | Biotechnology |
Gaya Pelaburan | Small Growth |
% Dimiliki oleh Orang Dalam | 0.09% |
% Dimiliki oleh Institusi | 81.26% |
Pemilikan
Nama | Tarikh | Syer Dipegang |
---|---|---|
Deep Track Capital, Lp | 31 Mar 2025 | 38,176,251 |
Vivo Capital, Llc | 31 Mar 2025 | 27,225,292 |
Vestal Point Capital, Lp | 31 Mar 2025 | 22,005,340 |
Julat 52 Minggu | ||
Julat Harga Sasaran | ||
Tinggi | 1.50 (Scotiabank, 17.19%) | Pegang |
Median | 1.25 (-2.34%) | |
Rendah | 1.00 (Goldman Sachs, -21.88%) | Jual |
Purata | 1.25 (-2.34%) | |
Jumlah | 1 Pegang, 1 Jual | |
Harga Purata @ Panggilan | 1.32 |
Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
---|---|---|---|---|
Goldman Sachs | 10 Jul 2025 | 1.00 (-21.88%) | Jual | 1.38 |
Scotiabank | 08 May 2025 | 1.50 (17.19%) | Pegang | 1.26 |
Tiada data dalam julat masa ini.
Tarikh | Jenis | Butiran |
---|---|---|
18 Jul 2025 | Pengumuman | Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
18 Jun 2025 | Pengumuman | Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
28 May 2025 | Pengumuman | Geron Announces Presentations at ASCO and EHA Underscoring RYTELO® (imetelstat) Efficacy and Safety Across Range of LR-MDS Patients, and Showcasing Momentum of Myelofibrosis Program |
19 May 2025 | Pengumuman | Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
07 May 2025 | Pengumuman | Geron Corporation Reports First Quarter 2025 Financial Results and Recent Business Highlights |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
Keuntungan Nyata | - |
Keuntungan Tidak Nyata | - |
Dividen Diterima 2025 | - |
Jumlah Untung | - |
Pulangan Purata | - |
Kuantiti (Beli) | - |
Purata Harga (Beli) | - |
Kuantiti (Jual) | - |
Purata Harga (Jual) | - |